The ready-to-use lentiviral particles of Lenti-CD20 CAR (scFv-ζ, Ofatumumab)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (Ofatumumab)-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|CAR-T-2-M302-4Z||Anti-CD20 scFv h(CD4-CD3ζ) CART, pCDCAR1|
|CAR-NK-2-M327-CZ||Anti-CD20 scFv h(b2c-CD3ζ) CARNK, pCDCAR1|
|CAR-T-3-M302-2BZ||Anti-CD20 scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1|
|VP-CAR-LC351||Lenti-CD20 CAR (scFv-CD28-41BB-CD3ζ, 1F5) Viral Particle|
|TCR-C034Z||Human anti-CD20 T cell receptor (A64), pCDTCR1|
|CAR-NK-2-M327-BG||Anti-CD20 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1|
|CAR-NK-1-M327-Z||Anti-CD20 scFv h(CD3ζ) CARNK, pCDCAR1|
|CAR-MZ055||Anti-CD20 (Ofatumumab) h(FcγRIII) CAR, pCDCAR1|
|VP-CAR-LC343||Lenti-CD20 CAR (scFv-CD3ζ, 1F5) Viral Particle|
|TCR-L129||Human anti-CD20 T cell receptor (A94), pCDTCR1|
Copyright © 2007 - 2018 Creative Biolabs. All Rights Reserved